Abstract
Potassium-competitive acid blocker vs proton-pump inhibitor in patients receiving antithrombotic therapy who are at high risk for gastrointestinal bleeding: Rationale and design of the randomized PROTECT- HBR trial.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have